SwePub
Sök i LIBRIS databas

  Extended search

(L773:1352 4585 OR L773:1477 0970) srt2:(2020-2024)
 

Search: (L773:1352 4585 OR L773:1477 0970) srt2:(2020-2024) > Comparative effecti...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006583naa a2200841 4500
001oai:DiVA.org:oru-75814
003SwePub
008190823s2020 | |||||||||||000 ||eng|
009oai:DiVA.org:umu-162860
009oai:DiVA.org:uu-438352
009oai:DiVA.org:liu-160049
009oai:prod.swepub.kib.ki.se:141632488
009oai:gup.ub.gu.se/292126
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-758142 URI
0247 a https://doi.org/10.1177/13524585198666002 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1628602 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4383522 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1600492 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1416324882 URI
0247 a https://gup.ub.gu.se/publication/2921262 URI
040 a (SwePub)orud (SwePub)umud (SwePub)uud (SwePub)liud (SwePub)kid (SwePub)gu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Granqvist, Mathiasu Karolinska Institutet4 aut
2451 0a Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS
264 c 2019-08-08
264 1b Sage Publications,c 2020
338 a print2 rdacarrier
500 a Funding Agency:Neuroförbundet, Stockholms Läns Landsting and Vetenskapsrådet 
500 a Funding Agencies|Neuroforbundet, Stockholms Lans Landsting and Vetenskapsradet
520 a BACKGROUND: Population-based real-world evidence studies of the effectiveness and tolerability of dimethyl fumarate in relation to common treatment alternatives are still limited.OBJECTIVE: To evaluate the clinical effectiveness and tolerability of dimethyl fumarate (DMF) as the initial and secondary treatment for relapsing-remitting multiple sclerosis (RRMS) patients compared with common treatment alternatives in Sweden.METHODS:  We conducted a nationwide retrospective observational cohort study of all RRMS patients identified through the Swedish MS registry initiating DMF (n = 641) or interferons/glatiramer acetate (IFN/GA; n = 555) as the initial therapy, or DMF (n = 703) or fingolimod (FGL; n = 194) after switch from IFN/GA between 1 January 2014 and 31 December 2016.RESULTS: The discontinuation rate was lower with DMF as the initial treatment than IFN/GA (adjusted hazard rate (HR): 0.46, 95% confidence interval (CI): 0.37-0.58, p < 0.001), but higher than FGL as the secondary treatment (HR: 1.51, CI: 1.08-2.09, p < 0.05). Annualized relapse rate (ARR) was lower with DMF compared to IFN/GA (0.04, CI: 0.03-0.06 vs 0.10, CI: 0.07-0.13; p < 0.05), but not FGL (0.03, CI: 0.02-0.05 vs 0.02, CI: 0.01-0.04; p = 0.41). Finally, time to first relapse (TTFR) was longer with DMF as the initial, but not secondary, therapy (p < 0.05 and p = 0.20, respectively).CONCLUSION: Our findings indicate that DMF performs better than IFN/GA as the initial treatment for RRMS. Compared to FGL, DMF displayed a lower tolerability, but largely similar effectiveness outcomes.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Hälsovetenskapx Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi0 (SwePub)303012 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Health Sciencesx Health Care Service and Management, Health Policy and Services and Health Economy0 (SwePub)303012 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng
653 a Multiple sclerosis
653 a dimethyl fumarate
653 a fingolimod
653 a glatiramer acetate
653 a interferon-beta
653 a relapsing-remitting
653 a dimethyl fumarate
653 a fingolimod
653 a glatiramer acetate
653 a interferon-beta
653 a Multiple sclerosis
653 a relapsing-remitting
7001 a Burman, Joachim,d 1974-u Uppsala universitet,Landtblom: Neurovetenskap,Uppsala Univ, Sweden4 aut0 (Swepub:uu)joabu293
7001 a Gunnarsson, Martin,d 1973-u Örebro universitet,Institutionen för medicinska vetenskaper,Örebro Univ, Sch Med Sci, Örebro, Sweden.4 aut0 (Swepub:oru)mign
7001 a Lycke, Jan,d 1956u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience4 aut0 (Swepub:gu)xlycja
7001 a Nilsson, Petrau Neurology Clinic, Skåne University Hospital, Lund, Sweden4 aut
7001 a Olsson, Tomasu Karolinska Institutet4 aut
7001 a Sundström, Peteru Umeå universitet,Klinisk neurovetenskap,Skane Univ Hosp, Neurol Clin, Lund, Sweden.;Umeå Univ, Dept Pharmacol & Clin Neurosci, Umeå, Sweden.4 aut0 (Swepub:umu)pesu0002
7001 a Svenningsson, Andersu Karolinska Institutet4 aut
7001 a Vrethem, Magnus,d 1955-u Linköpings universitet,Avdelningen för neurobiologi,Medicinska fakulteten,Region Östergötland, Neurologiska kliniken i Linköping4 aut0 (Swepub:liu)magvr07
7001 a Frisell, Thomasu Karolinska Institutet4 aut
7001 a Piehl, Fredriku Karolinska Institutet4 aut
7102 a Karolinska Institutetb Landtblom: Neurovetenskap4 org
7730 t Multiple Sclerosis Journald : Sage Publicationsg 26:12, s. 1532-1539q 26:12<1532-1539x 1352-4585x 1477-0970
8564 u https://doi.org/10.1177/1352458519866600y Fulltext
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-75814
8564 8u https://doi.org/10.1177/1352458519866600
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-162860
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-438352
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-160049
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:141632488
8564 8u https://gup.ub.gu.se/publication/292126

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view